Table 2 Univariate association of cefixime, azithromycin and ciprofloxacin resistance/susceptibility and patient characteristics, 2019

Site of infection (n = 2904)

 Urogenital (2076)^a

18 (0.9, 0.5–1.4)

0.40*

171 (8.2, 7.1–9.5)

1

1152 (55.5, 53.4–57.6)

1

 Anorectal (475)

1 (0.2, 0.0–1.2)

48 (10.1, 7.7–13.1)

1.25

0.89–1.75

298 (62.7, 58.3–67.0)

1.35

1.09–1.66

 Pharyngeal (262)^a

2 (0.8, 0.2–2.7)

35 (13.4, 9.8–18.0)

1.72

1.16–2.54

163 (62.5, 56.4–68.1)

1.33

1.02–1.74

 Other (91)

1 (1.1, 0.2–2.7)

9 (9.9, 5.3–17.7)

1.22

0.60–2.48

56 (61.5, 51.3–70.9)

1.28

0.83–1.97

Sexual orientation and sex (n = 1955)

 MSM (908)

3 (0.3, 0.1–1.0)

0.045*

75 (8.3, 6.6–10.2)

1

542 (59.7, 56.5–62.8)

1.9

1.54–2.42

 Male heterosexual (545)

4 (0.7, 0.3–1.9)

40 (7.3, 5.4–9.8)

0.88

0.59–1.31

285 (52.3, 48.1–56.5)

1.4

1.12–1.83

 Female (502)^b

8 (1.6, 0.8–3.1)

35 (7.0, 5.0–9.5)

0.83

0.59–1.26

217 (43.4, 39.1–47.8)

1

Previous gonorrhoea (n = 981)

 Yes (228)

1 (0.4, 0.0–2.4)

0.41*

18 (7.9, 6.0–9.8)

1.03

0.59–1.78

138 (60.5, 54.1–66.6)

1.68

1.24–2.28

 No (753)

1 (0.1, 0.0–0.8)

58 (7.7, 5.1–12.1)

1

359 (47.7, 44.1–51.2)

1

Concurrent chlamydia (n = 1075)

 Yes (228)

2 (0.9, 0.2–3.1)

0.20*

20 (8.8, 5.8–13.2)

1.02

0.61–1.71

95 (41.7, 35.5–48.2)

1

 No (847)

2 (0.2, 0.0–0.9)

73 (8.6, 7.0–10.7)

1

502 (59.3, 55.9–62.5)

2

1.51–2.75

HIV status (n = 1065)

 Positive (139)

0 (0.0, 0.0–2.7)

1.00*

15 (10.8, 6.6–17.0)

1.25

0.70–2.23

81 (59.3, 50.0–66.1)

1.2

0.84–1.72

 Negative (926)

3 (0.3, 0.1–0.9)

82 (8.9, 7.2–10.9)

1

498 (53.8, 50.6–57.0)

1

Age (n = 3106)

 < 25 years (883)^b

7 (0.8, 0.4–1.6)

1

0.72

75 (8.5, 6.8–10.5)

1

457 (51.9, 48.6–55.2)

1

 ≥ 25 years (2223)

15 (0.7, 0.4–1.1)

0.85

0.35–2.09

193 (8.7, 7.6–9.9)

1.02

0.77–1.35

1307 (58.8, 56.7–60.8)

1.3

1.13–1.55